Clinical outcomes in juvenile dermatomyositis.
Juvenile dermatomyositis is a chronic inflammatory illness of unknown etiology that affects primarily muscle and skin. It has an incidence of 2-3 per 1,000,000, per year. The disease can affect other organ systems, including the gastrointestinal tract, lungs, and heart. In addition, calcinosis is seen in one-third of patients. The mainstay of therapy is corticosteroids; some children require additional immunosuppressive agents because of corticosteroid resistance or intolerance. Functional outcomes have become good with modern treatments, but the disease remains chronic in a large number of children and sequelae are often seen.
Ramanan
A V
AV
Division of Rheumatology, Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.
Feldman
B M
BM
D002114:Calcinosis / Q000209:etiology / Q000473:pathology; D002675:Child, Preschool; D002908:Chronic Disease; D003882:Dermatomyositis / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008060:Lipodystrophy / Q000209:etiology / Q000473:pathology; D008833:Microcirculation / Q000473:pathology / Q000503:physiopathology; D009262:Nails / Q000098:blood supply; D011379:Prognosis; D016896:Treatment Outcome
D005938:Glucocorticoids; D007166:Immunosuppressive Agents